Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176794 | 1.00 | EPHX2 (0.43) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6176058 | 1.00 | EPHX2 (0.43) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6175781 | 1.00 | EPHX2 (0.43) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6176897 | 0.99 | EPHX2 (0.44) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6176893 | 0.99 | EPHX2 (0.44) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6176933 | 0.89 | EPHX2 (0.44) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6175862 | 0.87 | HSD17B10 (0.40) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL7950958 | 0.87 | HSD17B10 (0.40) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6178496 | 0.86 | EPHX2 (0.39) | EPHX2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6178497 | 0.86 | EPHX2 (0.39) | EPHX2GAAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2022-09-01 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190076538-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2019-03-14 | — | — | US | disclosed |
| US-10080805-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2018-09-25 | — | — | US | disclosed |
| US-20150050212-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2015-02-19 | — | — | US | disclosed |
| WO-2013126797-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2013-08-29 | — | — | WO | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-6344452-B1 | GASTRIN RECEPTOR ANTAGONIST, GASTROINTESTINAL DISORDERS, ETC | ZERIA PHARMACEUTICALS CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-20190076538-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-10080805-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | CCKBR, CCKAR, GABRB1 | EPHX2 2897/4885GAA 1647/4885KDM4E 2578/4885 |
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-20150050212-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885KDM4E 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.